Alternatives to heart transplantation. Symposium of the "Treatment of End-stage Heart and Lung Failure" working group on October 22, 2005 in Munich

TY - JOUR

T1 - Alternatives to heart transplantation. Symposium of the "Treatment of End-stage Heart and Lung Failure" working group on October 22, 2005 in Munich

AU - Strüber, M

AU - Lange, R

AU - Gummert, J F

AU - Beyersdorf, F

AU - Jurmann, M

AU - Schmid, C

AU - El Banayosy, A

AU - Hoppe, U C

AU - Steinbeck, G

AU - Reichenspurner, H

AU - Liebold, A

AU - Franz, W-M

AU - Ruhparwar, A

AU - Schmoeckel, M

AU - Working Group for Therapies of End Stage Cardiac and Pulmonary Disease

PY - 2007/9

Y1 - 2007/9

N2 - Heart transplantation is currently the treatment of first choice in patients with end-stage refractory heart failure. But already the demand for donor organs cannot be met, and patients face long waiting times for transplantation. In the future waiting times will become even longer as life expectancy increases and the number of heart-failure patients requiring transplantation grows. Consequently, in view of the poor prognosis of the disease in its advanced stages, alternatives to heart transplantation are increasingly gaining importance. In recent years new innovative treatment methods and techniques have been developed which have already proved clinically successful in patients with end-stage heart failure, especially as bridging measures. Some of these techniques appear suitable for long-term use and could therefore serve as an alternative to heart transplantation in some patients. Interesting new avenues of research may even lead to cardiac cell replacement therapies in the future. These approaches are currently undergoing initial clinical trials. This report presents surgical and cardiologic treatments for end-stage heart failure that have already been clinically investigated as well as techniques that are still in the preclinical stage and discusses their potential as alternatives to heart transplantation.

AB - Heart transplantation is currently the treatment of first choice in patients with end-stage refractory heart failure. But already the demand for donor organs cannot be met, and patients face long waiting times for transplantation. In the future waiting times will become even longer as life expectancy increases and the number of heart-failure patients requiring transplantation grows. Consequently, in view of the poor prognosis of the disease in its advanced stages, alternatives to heart transplantation are increasingly gaining importance. In recent years new innovative treatment methods and techniques have been developed which have already proved clinically successful in patients with end-stage heart failure, especially as bridging measures. Some of these techniques appear suitable for long-term use and could therefore serve as an alternative to heart transplantation in some patients. Interesting new avenues of research may even lead to cardiac cell replacement therapies in the future. These approaches are currently undergoing initial clinical trials. This report presents surgical and cardiologic treatments for end-stage heart failure that have already been clinically investigated as well as techniques that are still in the preclinical stage and discusses their potential as alternatives to heart transplantation.

KW - Animals

KW - Cardiac Surgical Procedures

KW - Cardiotonic Agents/therapeutic use

KW - Heart Failure/surgery

KW - Heart, Artificial

KW - Heart-Assist Devices/classification

KW - Humans

KW - Myoblasts/transplantation

KW - Pacemaker, Artificial

KW - Stem Cell Transplantation

KW - Tissue Engineering

KW - Transplantation, Heterologous

U2 - 10.1055/s-2007-965414

DO - 10.1055/s-2007-965414

M3 - SCORING: Journal article

C2 - 17764064

VL - 55 Suppl 2

SP - 147

EP - 167

JO - THORAC CARDIOV SURG

JF - THORAC CARDIOV SURG

SN - 0171-6425

ER -